Sophia Genetics Announces IPO And Cancer Data Partnership With GE Healthcare

Bioinformatic company Sophia Genetics seeks to solicit $100 million for investment in an IPO with GE Healthcare. Morgan Stanley, J.P. Morgan, Cowen, and Credit Suisse will collaborate in managing book-running duties for this venture. There has been no indication of the IPO’s pricing parameters or the number of shares to be offered. Trading with the NASDAQ tag SOPH, the company has to date raised about $251 million in private equity. A Series F round last October accounted for $110 million of that total.

Sophia Genetics, which has counterpart headquarters in Boston and Switzerland, is known for its Data-Driven Medicine platform, a cloud-native genomic analytics SaaS offering. It filters through multimodal datasets for deep insight and analysis. DDM and similar solutions can be found in the systems of over 750 laboratories, biopharma institutions, and clinics around the world.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The company has also recently signed a letter of intent with GE Healthcare to work together in developing AI-powered workflow and analytics technologies. GE will incorporate its medical imaging and monitoring technologies and Edison platform-enabled data aggregation with Sophia Genetics’ DDM. Their solutions will enhance the efficacy of treatment combinations based on cancer patients’ genetic and tumor profiles.